Details of the Drug
General Information of Drug (ID: DMTEY8W)
Drug Name |
E-6276
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-(2-Benzhydrylideneaminooxy-ethyl)-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid; UNII-BGU9MZ2G30; BGU9MZ2G30; CHEMBL473104; 159094-94-7; Tocris-1779; Lopac-N-142; Biomol-NT_000271; AC1L1IC7; Lopac0_000880; SCHEMBL5969062; GTPL4669; BPBio1_000948; CTK0H8642; CHEBI:92744; DTXSID30166582; ZINC1534967; BDBM50426075; BDBM50080344; AKOS030543350; CCG-204962; 3-Pyridinecarboxylic acid, 1-(2-(((diphenylmethylene)amino)oxy)ethyl)-1,2,5,6-tetrahydro-; NCGC00015712-05; NCGC00015712-02; NCGC00025293-03; NCGC00025293-02; NCGC00015712-04; NCGC00025293-01; NCGC00015712-03; NCGC00015712-01; LS-187291
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 350.4 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 1.5 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 7 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Schizophrenia | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | 6A20 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References